Skandinaviska Enskilda Banken Ab (Publ) Iovance Biotherapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $20.7 Billion
- Q2 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 113,952 shares of IOVA stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,952
Previous 113,952
-0.0%
Holding current value
$1.1 Million
Previous $1.69 Million
45.91%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding IOVA
# of Institutions
323Shares Held
239MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$249 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$249 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$231 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$204 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$121 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.52B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...